Method of detecting truncated epidermal growth factor receptors
US4933294A · kind A · utility
Assignees
Inventors
Key dates
| Filing date | Sep 30, 1985 |
| Grant date | Jun 12, 1990 |
| Priority date | — |
| Expiry date | Sep 30, 2005 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S436/817
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Neoplastic and other diseases can be diagnosed by assaying a human test sample e.g. body fluid, tissue or cultured tumor explant cells, for structurally altered or abnormally expressed growth factor receptors or for the RNA transcripts of genes which encode them. For example, the assay can be for truncated EGF receptor having at least a portion of its mature amino terminus deleted. Antibodies, capable of binding a predetermined amino acid sequence within the EGF receptor, are also useful in diagnosis and therapy as are conjugates of an immunogenic polymer bound to a polypeptide fragment of EGF receptor. DNA and RNA encoding EGF receptor or fragments thereof are also described.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.